An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers

SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this study in two phases: dose escalation and dose expansion.

Start Date18 Aug 2022

Sponsor / Collaborator

Shattuck Labs, Inc.

NCT05275439

/ CompletedPhase 1

An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination with Azacitidine or with Azacitidine and Venetoclax for the Treatment of Subjects with Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.

Start Date17 Mar 2022

Sponsor / Collaborator

Shattuck Labs, Inc.

NCT04502888

/ TerminatedPhase 1

Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L), Administered Intratumorally in Subjects With Cutaneous Squamous Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck

This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous squamous cell carcinoma (CSCC) or squamous cell carcinoma of the head and neck (SCCHN).

Start Date17 Sep 2020

Sponsor / Collaborator

Shattuck Labs, Inc.

100 Clinical Results associated with SL-172154

100 Translational Medicine associated with SL-172154

100 Patents (Medical) associated with SL-172154

Literatures (Medical) associated with SL-172154

01 Jan 2025·Journal for ImmunoTherapy of Cancer

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer

Article

Author: Lakhani, Nehal J ; Hamilton, Erika ; Ma, Bo ; Pandite, Lini ; Metenou, Simon ; Call, Justin ; Richardson, Debra L ; Wang, Guanfang ; Huguet, Jade ; Rangwala, Fatima ; Van Le, Linda ; Offman, Elliot ; Stewart, Daphne ; Dockery, Lauren E

Background:

SL-172154 is a hexameric fusion protein adjoining the extracellular domain of SIRPα to the extracellular domain of CD40L via an inert IgG4-derived Fc domain. In preclinical studies, a murine equivalent SIRPα-Fc-CD40L fusion protein provided superior antitumor immunity in comparison to CD47- and CD40-targeted antibodies. A first-in-human phase I trial of SL-172154 was conducted in patients with platinum-resistant ovarian cancer.

Methods:

SL-172154 was administered intravenously at 0.1, 0.3, 1.0, 3.0, and 10.0 mg/kg. Dose escalation followed a modified toxicity probability interval-2 design. Objectives included evaluation of safety, dose-limiting toxicity, recommended phase II dose, pharmacokinetic (PK) and pharmacodynamic (PD) parameters, and antitumor activity.

Results:

27 patients (median age 66 years (range, 33–85); median of 4 prior systemic therapies (range, 2–9)) with ovarian (70%), fallopian tube (15%), or primary peritoneal (15%) cancer received SL-172154. Treatment-emergent adverse events (TEAEs) were reported for 27 patients (100%), with 24 (88.9%) having a drug-related TEAE and infusion-related reactions being the most common. 12 patients (44.4%) had grade 3/4 TEAEs, and half of these patients (22.2%) had a drug-related grade 3/4 TEAE. There were no fatal adverse events, and no TEAEs led to drug discontinuation. SL-172154 Cmaxand area under the curve increased with dose with greater than proportional exposure noted at 3.0 and 10.0 mg/kg. CD47 and CD40 target engagement on CD4+T cells and B cells, respectively, approached 100% by 3.0 mg/kg. Dose-dependent responses in multiple cytokines (eg, interleukin 12 (IL-12), IP-10) approached a plateau at ≥3.0 mg/kg. Paired tumor biopsies demonstrated a shift in macrophages from an M2- to an M1-dominant phenotype and increased infiltration of CD8 T cells. PK/PD modeling showed near maximal margination of B cells and a dose-dependent production of IL-12 nearing a plateau at >3.0 mg/kg. The best response was stable disease in 6/27 (22%) patients.

Conclusions:

SL-172154 was tolerable as monotherapy and induced, dose-dependent, and cyclical immune cell activation, increases in multiple serum cytokines, and trafficking of CD40-positive B cells and monocytes following each infusion. The safety, PK, and PD activity support 3.0 mg/kg as a safe and pharmacologically active dose.

Trial registration number:

NCT04406623.

News (Medical) associated with SL-172154

14 Nov 2024

·www.globenewswire.com

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today reported financial results for the quarter ended September 30, 2024 and provided recent business highlights. “Last month we announced a strategic shift to focus on the development of SL-325, a first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 signaling pathway. We are underway with IND-enabling, non-human primate studies to evaluate the safety, pharmacokinetic and pharmacodynamic profile of SL-325,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “As of this month, we have substantively completed our restructuring plans to focus on the development of SL-325 and are well-positioned to fund our planned operations into 2027.” Upcoming Events Shattuck plans to attend the following investor conferences. Details will be included on the Events & Presentations section of the Company’s website. Piper Sandler & Co. 36th Annual Healthcare Conference (New York City, NY), December 3–5, 2024. Taylor Schreiber, M.D., Ph.D., CEO of Shattuck Labs will participate in a presentation on December 3, 2024.Evercore ISI 7th Annual HealthCONx Conference (Miami, FL), December 3–5, 2024. The Company’s management will participate in a fireside chat on December 4, 2024. Third Quarter 2024 Financial Results Cash and Cash Equivalents and Investments: As of September 30, 2024, cash and cash equivalents and investments were approximately $90.1 million, as compared to $101.1 million as of September 30, 2023.Research and Development (R&D) Expenses: R&D expenses were $16.3 million for the quarter ended September 30, 2024, as compared to $24.2 million for the quarter ended September 30, 2023.General and Administrative (G&A) Expenses: G&A expenses were $4.6 million for the quarter ended September 30, 2024, as compared to $5.1 million for the quarter ended September 30, 2023.Net Loss: Net loss was $16.7 million for the quarter ended September 30, 2024, or $0.33 per basic and diluted share, as compared to a net loss of $27.5 million for the quarter ended September 30, 2023, or $0.65 per basic and diluted share. Financial Guidance Shattuck has effectuated its restructuring plan to prioritize the development of the DR3 program and align the Company’s cost and workforce structure with the its current goals and clinical development strategy. The Company has substantially completed the reduction in force associated with the discontinuation of SL-172154. Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from its Phase 1 clinical trial of SL-325. This cash runway guidance is based on the Company’s current operational plans and excludes any additional capital that may be received, proceeds from potential business development transactions, and/or additional costs associated with additional development activities that may be undertaken. About SL-325 SL-325 is a first-in-class Death Receptor 3 (DR3) antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. Shattuck’s preclinical studies demonstrate high affinity binding, superior efficacy over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is currently being evaluated in a GLP toxicology study in non-human primates, with an IND filing expected in the third quarter of 2025. About Shattuck Labs, Inc. Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases and cancer. The Company is developing a potentially first-in-class antibody for the treatment of IBD and other inflammatory autoimmune diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, our expectations regarding: plans for our preclinical studies, clinical trials and research and development programs, particularly with respect to SL-325; plans for the realignment of our strategic pipeline and discontinuation of clinical development of SL-172154; the anticipated timing of any regulatory filings for SL-325; the anticipated timing of our preclinical studies and clinical trials for SL-325; the clinical benefit, safety and tolerability of SL-325; the effects of the proposed restructuring and reduction in force on the Company’s results of operations and financial condition; and expectations regarding the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; our expectations regarding the overall benefit of the strategic prioritization of our pipeline; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent disclosure documents filed with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD. Investor & Media Contact: Conor RichardsonVice President of Investor RelationsShattuck Labs, Inc.InvestorRelations@ShattuckLabs.com SHATTUCK LABS, INC. CONDENSED BALANCE SHEETS(In thousands) September 30, 2024 December 31,2023 (unaudited) Assets Current assets: Cash and cash equivalents$43,829 $125,626 Investments 46,229 4,999 Prepaid expenses and other current assets 8,682 12,595 Total current assets 98,740 143,220 Property and equipment, net 10,827 13,804 Other assets 2,153 2,540 Total assets$111,720 $159,564 Liabilities and Stockholders’ Equity Current Liabilities: Accounts payable$2,927 1,587 Accrued expenses 9,474 9,866 Total current liabilities 12,401 11,453 Non-current operating lease liabilities 2,742 3,406 Total liabilities$15,143 $14,859 Stockholders’ equity: Common stock 5 5 Additional paid in capital 459,561 451,006 Accumulated other comprehensive income 52 4 Accumulated deficit (363,041) (306,310)Total stockholders' equity 96,577 144,705 Total liabilities and stockholders' equity$111,720 $159,564 SHATTUCK LABS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (In thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Collaboration revenue$2,997 $686 $5,721 $943 Operating expenses: Research and development 16,313 24,211 51,816 59,083 General and administrative 4,604 5,073 14,831 14,866 Expense from operations 20,917 29,284 66,647 73,949 Loss from operations (17,920) (28,598) (60,926) (73,006)Other income 1,245 1,057 4,195 3,395 Net loss$(16,675) $(27,541) $(56,731) $(69,611)Unrealized gain on investments 57 81 48 884 Comprehensive loss$(16,618) $(27,460) $(56,683) $(68,727) Net loss per share – basic and diluted$(0.33) $(0.65) $(1.12) $(1.64)Weighted-average shares outstanding – basic and diluted 50,833,538 42,477,642 50,730,767 42,461,644

Phase 1Financial StatementPROTACs

02 Oct 2024

·pipelinereview.com

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued – – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – AUSTIN, TX and DURHAM, NC, USA I October 01, 2024 I Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154. The Company will turn its focus to SL-325, its DR3 antagonist antibody, and plans initial clinical development in patients with IBD, where TL1A/DR3 blocking antibodies have demonstrated compelling monotherapy efficacy. “We are disappointed that the promising complete remission rates we previously shared from our Phase 1 clinical trial did not translate to clinically meaningful improvements in median overall survival for TP53m AML and HR-MDS patients treated with SL-172154 in combination with azacitidine. We thank our clinical team and investigators for conducting an excellent clinical study, yet we must accept this result as it stands and move on to other opportunities with a higher probability of success,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. Dr. Schreiber continued, “We are announcing a strategic shift to focus on SL-325, a DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 signaling pathway. We believe SL-325 could be a first-in-class DR3 receptor blocking antibody, and that this approach will prove more potent than blocking TL1A, for many of the same reasons that blocking PD-1 has proven more potent than blocking PD-L1. This strategic shift in our clinical development plans and subsequent realignment of our organization with an approximate 40% reduction in workforce will allow us to use our resources most efficiently to position Shattuck for long-term success. I would like to express my gratitude to the patients who participated in our clinical trials to date as well as to the Shattuck team members who were impacted by this realignment.” Top-line Phase 1B SL-172154 Clinical Trial Results HR-MDS TP53m AML Corporate Updates Financial Guidance Update As of June 30, 2024, cash and cash equivalents and investments were $105.3 million. Shattuck has implemented a restructuring plan to prioritize the development of the Company’s DR3 program. The plan is intended to optimize the Company’s cost structure by aligning the size and structure of its workforce with the Company’s current goals and strategy, following the discontinuation of SL-172154. Approximately 40% of Shattuck’s workforce will be impacted by the changes. The Company expects to complete the reduction in force in the fourth quarter of 2024. Given the changes to Shattuck’s operations and cost structure, the Company believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from its planned Phase 1 clinical trial of SL-325. This cash runway guidance is based on the Company’s current operational plans and excludes any additional capital that may be received, proceeds from potential business development transactions, and/or additional costs associated with additional development activities that may be undertaken. Shattuck Labs Investor Call and Webcast Shattuck will host a conference call and webcast at 8:00 a.m. ET on Tuesday, October 1, 2024, to discuss clinical data from SL-172154 and outline a strategic pipeline prioritization to focus on SL-325, a first-in-class DR3 antagonist targeting the TL1A/DR3 signaling pathway. Participants are invited to listen by dialing (800) 715-9871 (domestic) or +1 (646) 307-1963 (international) five minutes prior to the start of the call and providing the passcode 6989140. A live webcast presentation will be available here or on the company’s website at www.ShattuckLabs.com under Events & Presentations . A replay of the webcast will be archived on the company’s website following the presentation. About Shattuck Labs, Inc. Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases and cancer. Shattuck is developing a potentially first-in-class antibody for the treatment of IBD and other inflammatory autoimmune diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com . SOURCE: Shattuck Labs

Phase 1Financial Statement

02 Oct 2024

·www.pharmaceutical-technology.com

Shattuck Labs stock craters following pipeline and job cuts

Following the restructuring news, Shattuck’s stock was down by 44.99% at market close on 1 October, compared to market close on the previous day. Shutterstock: paper cut design / Shutterstock. Shattuck Labs has dropped by nearly 45% after it announced plans to reduce its headcount and discontinue its lead cancer therapy programme, SL-172154. The restructuring decision was made after interim data from a Phase Ib trial (NCT05275439) showed a lack of a definitive overall survival (OS) benefit in patients receiving SL-172154. The company added that the ‘modest’ improvements in the OS seen in Phase I would likely erode in larger late-stage studies. Following the announcement, Shattuck’s stock was down by 44.99% at market close on 1 October, compared to market close on the previous day. The company’s market cap currently stands at $81.6m. SL-172154 is a cluster of differentiation 47 (CD47) inhibitors, which were investigated as a treatment for myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). In February, Shattuck licensed out multiple potential drug candidates, including SL-172154, to Ono Pharmaceuticals in a deal worth more than $227m. As part of the restructuring, the companies have mutually terminated the agreement and Shattuck is “no longer required to satisfy any remaining performance obligations and will not receive any future research activity reimbursements or upfront, milestone, or royalty payments from Ono”. See Also: ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy The cost-saving measures also cull 40% of the workforce by the end of the year and will cost between $1.5m and $1.75m. Shattuck reported cash reserves of $105.3m as of 30 June, as per the latest SEC filing by the company. The company plans to funnel its remaining resources into developing its antibody therapy, SL-325. The DR3 antagonist acts by modulating adaptive immunity, as DR3 is expressed on the cell surface of various immune cells. Shattuck is developing SL-325 as a treatment for inflammatory autoimmune diseases, including inflammatory bowel disease (IBD). The company plans to file an investigational new drug application (IND) for SL-325 in Q3 2025. Shattuck noted that it has sufficient funds to finance beyond its planned Phase I clinical trial of SL-325 and into 2027. Following the recent round of lay-offs, Shattuck joins the list of pharmaceutical companies, including Atreca , Candel Therapeutics , Cidara Therapeutics , Kinnate Bio , and NexImmune , which have cut their workforces to reallocate funds into their clinical development pipelines in the last few months.

Phase 1ImmunotherapyLicense out/inIND

100 Deals associated with SL-172154

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platinum-Resistant Fallopian Tube Carcinoma	Phase 1	United States	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Fallopian Tube Carcinoma	Phase 1	Canada	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Fallopian Tube Carcinoma	Phase 1	Spain	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Fallopian Tube Carcinoma	Phase 1	United Kingdom	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Ovarian Carcinoma	Phase 1	United States	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Ovarian Carcinoma	Phase 1	Canada	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Ovarian Carcinoma	Phase 1	Spain	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Ovarian Carcinoma	Phase 1	United Kingdom	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Primary Peritoneal Carcinoma	Phase 1	United States	Shattuck Labs, Inc.	18 Aug 2022
Platinum-Resistant Primary Peritoneal Carcinoma	Phase 1	Canada	Shattuck Labs, Inc.	18 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04502888 (CTgov)	Phase 1	Squamous Cell Carcinoma of Head and Neck \| Cutaneous Squamous Cell Carcinoma of the Head and Neck \| Cutaneous Squamous Cell Carcinoma	5	SL-172154	yqohytswwd = fxfunxiunj ncfwuzafei (xzlijubevs, upafulafih - mwnncedirn)	-	25 Mar 2025
NCT04406623 (First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154, CTgov)	Phase 1	Ovarian Cancer \| Primary peritoneal carcinoma \| Ovarian Epithelial Carcinoma ... View more	27	SL-172154	beuriepftd = drkjjpyrol xfrswkzyyj (qdrxlbkitn, cdpfbjjgam - ibymfkaasr)	-	30 Jan 2025
NEWS Manual	Not Applicable	Acute Myeloid Leukemia	-	SL-172154	vtmirackom(kkdohhmkhl) = neiysnvnnk vnqmcsaqsf (hgrvnoaruv )	Negative	01 Oct 2024
				azacitidine	vtmirackom(kkdohhmkhl) = pwxocpjoca vnqmcsaqsf (hgrvnoaruv )
NCT05483933 (Biospace) Manual	Phase 1	Platinum-Resistant Ovarian Carcinoma	21	SL-172154 + PLD	ugbswqaakx(vpucclvhnh) = qpjmssdalx cykeowdpyg (aooxyjdeqo )	Positive	14 Jun 2024
				SL-172154 + Mirvetuximab	-
NCT05275439 (GlobeNewswire) Manual	Phase 1	Acute Myeloid Leukemia \| Myelodysplastic Syndromes TP53 Mutation	45	SL-172154+ Azacitidine (HR-MDS)	arrikuaunw(jkykjqmitm) = pewsqsedbi hiwidtaeap (zrylxastyo ) View more	Positive	14 Jun 2024
				SL-172154+ Azacitidine (TP53m AML)	arrikuaunw(jkykjqmitm) = nfzgakpfvh hiwidtaeap (zrylxastyo ) View more
EHA2024 Manual	Phase 1	Acute Myeloid Leukemia \| High Risk Myelodysplastic Syndrome TP53 Mutation	39	SL-172154 (Azacitidine40L, 154) + Azacitidine	uxcnuftabe(cgpwumihao) = wtglykievp ttvttddmev (ohoccutumd ) View more	Positive	14 May 2024
ASH2023 Manual	Phase 1	Acute Myeloid Leukemia \| Myelodysplastic Syndromes TP53 Mutation	37	SL-172154	cwmtrkbjdi(glqahnaovd) = eczktvhnax oydyunhvtd (uikhrbyync ) View more	Positive	11 Dec 2023
				SL-172154+Azacitidine	cwmtrkbjdi(glqahnaovd) = futsregllh oydyunhvtd (uikhrbyync ) View more
NCT04406623 (ASCO 12023 \| ASCO 22023) Manual	Phase 1	Platinum-Resistant Ovarian Carcinoma	27	SL-172154	towxsphgux(dqqftjmolo) = Treatment-emergent AEs (>15%) regardless of grade (G) included infusion related reaction (IRR) (67%), fatigue (44%), nausea (33%), back pain (26%), constipation, diarrhea (both 22%), decreased appetite and pruritus (both 19%). crdlgkrebj (vbuynaubbb ) View more	Positive	31 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis